CollPlant Biotechnologies Ltd. (CLGN) intrinsic value & 10-year financials
CollPlant Biotechnologies Ltd. (CLGN) has a Graham intrinsic value of $0.66 per share. Over the last 10 fiscal years revenue grew 22.1% a year to $2.4M, with an average return on invested capital of -206.5%.
- Graham intrinsic value
- $0.66
- Revenue (FY2025)
- $2.4M
- Revenue growth (10-yr CAGR)
- 22.1%
- ROIC (10-yr avg)
- -206.5%
- Free cash flow (FY2025)
- -$9.4M
CLGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.4M | -$11.5M | -$0.94 | -$9.4M | -484.3% | -361.7% |
| FY2024 | $515.0K | -$16.6M | -$1.45 | -$14.6M | -3349.7% | -214.8% |
| FY2023 | $11.0M | -$7.0M | -$0.62 | -$3.7M | -68.5% | -78.8% |
| FY2022 | $299.0K | -$16.9M | -$1.53 | -$15.0M | -5718.1% | -83.3% |
| FY2021 | $15.6M | $237.0K | $0.02 | $1.1M | 0.4% | 1.2% |
| FY2020 | $6.1M | -$5.8M | -$0.84 | -$4.9M | -91.2% | -151.9% |
| FY2019 | $2.3M | -$11.2M | -$2.23 | -$7.2M | -329.2% | -319.1% |
| FY2018 | $5.0M | -$6.2M | — | -$2.0M | -84.7% | -331.2% |
| FY2017 | $481.0K | -$6.0M | — | -$18.0M | -1244.5% | -319.1% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CollPlant Biotechnologies Ltd revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CollPlant Biotechnologies Ltd has historically struggled to out-earn its cost of capital, averaging just -19.8% ROIC.
Over the decade, CollPlant Biotechnologies Ltd shows that management has aggressively returned capital to shareholders by retiring 87.9% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CollPlant Biotechnologies Ltd is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.66 per share.